Yissum Technology Transfer Company of the Hebrew University of Jerusalem ended 2007 with $51 million revenue, 27% more than in 2006.
Nava Swersky Sofer congratulating Israel on it's 60th anniversary on a special Forbes edition.
The unique case-controlled DNA database for genetic association studies will allow the scientific community to access DNA samples directly via the Internet (www.hugr.org) and test genes of interest.
The Hebrew University Genetic Resource (HUGR) platform includes 15,000 DNA samples of Ashkenazi Jews
Scientists from the School of Pharmacy at the Hebrew University of Jerusalem discovered a novel orally available drug that prevents metastasis formation in various types of cancers.
Yissum spin-off Morria Biopharmaceuticals, a biopharmaceutical company focused on the development of novel anti- inflammatory drugs, announced the preliminary safety results from its Phase I safety and tolerability study of MRX-4 in 16 patients suffering from allergic rhinitis (AR).
Globes article portraying Israeli Technology Transfer (Hebrew)
The Acetylcholinesterase (AChE) Program is being conducted
under the agreement the Company entered into with Yissum Research and
Development Company, the technology transfer arm of the Hebrew University of
Jerusalem, Israel, and the Boyce Thompson Institute, Inc.
Israel 21c portraying Nava Swersky Sofer, Yissum's President & CEO
The FDA approved the trial at 5 Israeli hospitals and one in Arizona.
Yissum and Eucalyptus Biosciences Sign Licensing Agreement for the Development of a Small Molecule for the Treatment of Neurodegenerative Diseases
Israel's Universities and institutes are all about developing and selling technology
Jerusalem-based Yissum has formed a spin-off company - Nanolymf, which will
be dedicated to advancing a nanotechnology controlled-release drug delivery platform.
The Israeli company is developing treatments for various neurological diseases based on a technology licensed from Yissum
One of Israel's leading biochemists, Prof. Yechezkel Barenholz of the Hebrew University's Hadassah Medical School, has used liposomes to design better drug delivery systems that extend and improve the lives of cancer patients around the world.
US-Israeli biopharmaceutical start-up Medgenics Inc. raised a gross ₤3.3 million in its IPO on London’s Alternative Investment Market (AIM) on Thursday at a company value of ₤10.4 million, after money. The company, which is based on Yissum's technology, offered 104.1 million shares at ₤0.10 per share.
People call what Target-In is doing 'guided missiles', and in a way that's exactly what the company's technology is: a guided missile that can recognize and kill inflamed cells from tumors and other diseases. But Target-In's technology is more sophisticated than that. The technology doesn't just shoot diseased cells down, it makes them commit suicide.
BioLineRx today announced that it has signed a worldwide exclusive
license agreement with Yissum, the technology transfer company of the Hebrew University of Jerusalem, and Hadasit, the technology transfer company of Hadassah medical organization, for the development and commercialization of BL-4060.
Indian API company Century Pharmaceutical has already promised to invest $1 million.